Horizon's target identification platform SyntheTx™ sees convergence of three powerful technologies:
Synthetic Lethality: Loss of either gene A or gene B in normal cells is compensated by action of the remaining gene. Lethality occurs in tumor cells when a mutation in one of these genes leaves the cell vulnerable to loss of the other gene by inhibition:
Deploying X-MAN® cell lines in cell-based synthetic lethality screens enables the identification of putative patient populations that exhibit downstream genes/proteins that represent novel targets of therapeutic intervention.
These technology platforms enable the performance of simple, high-throughput and rational RNAi screens to be performed that:
X-MAN® models are currently available for many of the most common cancer mutations but there is much work to do to map the entire cancer genome landscape with less common genotypes.
These models are essential to understand how cancer genes affect pathways and to define the next generation of drug targets that demonstrate selective anti-cancer effects.